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ORIGINAL ARTICLE
Concordant bone marrow involvement of diffuse large B-cell
lymphoma represents a distinct clinical and biological entity
in the era of immunotherapy
Z Yao1,2,20, L Deng3,20, ZY Xu-Monette2, GC Manyam4, P Jain5, A Tzankov6, C Visco7, G Bhagat8, J Wang4, K Dybkaer9, W Tam10, ED Hsi11,
JH van Krieken12, M Ponzoni13, AJM Ferreri13, MB Møller14, JN Winter15, MA Piris16, L Fayad5, Y Liu1, Y Song1, RZ Orlowski5,
H Kantarjian5, LJ Medeiros2, Y Li17, J Cortes5 and KH Young2,18
In diffuse large B-cell lymphoma (DLBCL), the clinical and biological signiﬁcance of concordant and discordant bone marrow (BM)
involvement have not been well investigated. We evaluated 712 de novo DLBCL patients with front-line rituximab-containing
treatment, including 263 patients with positive and 449 with negative BM status. Compared with negative BM disease, concordant
BM adversely impacted overall and progression-free survival, independent of the International Prognostic Index (IPI) and cell-of-
origin classiﬁcation. Once BM is concordantly involved, poor prognosis was not associated with the extent of BM involvement.
Conversely, patients with discordant BM showed favorable overall survival similar to stage I–II DLBCL. A BM-adjusted IPI, using three
parameters: concordant BM involvement, age 460 years, and performance status 41, improves the risk stratiﬁcation for DLBCL
with positive BM. Intensive immunochemotherapy seemingly rendered survival beneﬁt for patients with concordant BM, as did
rituximab maintenance for the discordant BM group. Frequently revealing adverse clinical and molecular characteristics, patients
with concordant BM demonstrated gene expression signatures relevant to tumor cell proliferation, migration and immune escape.
In conclusion, clinical and biological heterogeneity is seen in DLBCL with positive BM but concordant BM involvement represents a
distinct subset with unfavorable gene signatures, high-risk clinicopathologic features and poor prognosis.
Leukemia (2018) 32, 353–363; doi:10.1038/leu.2017.222
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common type
of lymphoma and is highly heterogeneous in regard to clinical
manifestations, biological features and prognosis. The introduc-
tion of rituximab (R) combined with cyclophosphamide, doxor-
ubicin, vincristine and prednisone (CHOP) has resulted in
improved outcome in DLBCL patients; however, variable prognosis
is present, and identifying distinct subsets for prognostication and
therapeutic decisions is essential.1–3
Approximately 11–34% of patients have bone marrow (BM)
involvement when DLBCL is initially diagnosed.4–6 In most
patients, BM is involved by large B-cell lymphoma (concordant
disease), but a subset of patients have small cell low-grade
lymphoma in the BM (discordant disease).4,7–10 BM involvement
by lymphoma is clinically recognized as advanced disease and
contributes to higher International Prognostic Index (IPI) scores.
The IPI, a powerful clinical tool for risk-stratiﬁcation of DLBCL, is
calculated by using ﬁve clinical parameters: age 460 years, Ann
Arbor stage III–IV, Eastern Cooperative Oncology Group perfor-
mance status (PS) 41, elevated serum lactate dehydrogenase
(LDH), and involvement of more than one extranodal site.11,12 Of
interest, some studies have reported that the impact of
concordant vs discordant BM involvement on overall survival
(OS) and progression-free survival (PFS) was different.4,7–10 Owing
to the limited number of enrolled patients with positive BM and
the dissimilarity of design and inclusion criteria in earlier studies,
the consensus regarding the prognostic impact of concordant vs
discordant BM is controversial and needs to be validated in a
larger series. Furthermore, whether differences between concor-
dant and discordant BM involvement can be optimized in an
adjusted IPI for risk stratiﬁcation is unknown.
In addition to the IPI, cell-of-origin (COO) classiﬁcation deﬁned
by gene expression proﬁling (GEP) or immunohistochemistry
surrogates has been widely adopted, which classiﬁes DLBCL cases
into germinal center B-cell-like (GCB) subtype and activated B-cell-
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like/non-GCB subtype, with the former associated with better
survival.13–17 Meanwhile, several other biomarkers, including CD5,
p53, MYC expression, MYC/BCL2 co-expression, TP53 mutation,
BCL2 or MYC rearrangement and MYC/BCL2 double hit, have been
implicated in mechanisms of disease and have been suggested as
predictors of poor prognosis in DLBCL.18–24 Thus far, no large
studies have explored the relationship between these high-risk
pathologic features and the various types of BM involvement in
DLBCL patients.
To address these equivocal questions and elucidate the role of
BM involvement in DLBCL patients, we conducted a large study of
de novo DLBCL treated with immunochemotherapy. We analyzed
GEP and molecular analyses to better characterize the pathologic
features of concordant BM involvement.
MATERIALS AND METHODS
Patients
The study cohort included 263 de novo DLBCL patients with positive BM
involvement and 449 patients with negative BM. This study is part of the
International DLBCL Consortium Program. All patients needed to meet the
following prerequisites: they were treated with front-line rituximab-
containing standard protocols; age 16 years or older with a conﬁrmed
diagnosis of DLBCL according to 2016 WHO criteria25 on pathology review;
they underwent a pretreatment bilateral or unilateral posterior superior
iliac crest BM biopsy (with both biopsy and aspiration); they had available
BM slides for a central review in case of positive for lymphoma in BM.
Patients were excluded if they had primary central nervous system (CNS),
cutaneous, or mediastinal DLBCL, HIV infection, an identiﬁed past history of
lymphoma or another malignancy that was uncontrolled. The study were
reviewed and approved by the institutional review boards of each
participating center, and the overall study was approved by the
institutional review board of the University of Texas MD Anderson Cancer
Center.
Disease staging and treatment response of all patients were assessed by
the Ann Arbor system26 and the Revised International Working Group
response criteria,27 respectively. A modiﬁcation of the Ann Arbor
classiﬁcation deﬁned stage I–II as limited DLBCL and stage III–IV as
advanced DLBCL.28 The interpretation of TP53 mutations by gene
sequencing, MYC and BCL2 rearrangements by ﬂuorescence in situ
hybridization analyses, and p53, CD5, BCL2 and MYC expression by
immunohistochemistry staining were based on published data.17,20,22,23
A cut-off value for a high Ki-67 index was considered to be 70%. gene
expression proﬁling of specimens involved by DLBCL was performed and
the COO classiﬁcation was analyzed by GEP and the immunohistochem-
istry algorithm based on Choi and Visco/Young’s algorithm methods.17
Deﬁnition and classiﬁcation of BM involvement
BM trephine biopsies, clot sections and aspirate smears from DLBCL
patients who were reported to have positive BM were centrally reviewed.
Utilizing morphology and immunohistochemistry, the types and extent of
BM involvement were identiﬁed.9,29–31 Concordant BM disease was deﬁned
by the involved BM area consisting of mostly large non-cleaved DLBCL
cells; discordant BM was deﬁned by the involved BM consisting of mostly
small and low-grade lymphoma cells. We deﬁned extensive BM involve-
ment at 25% and higher replacement of the medullary space; less than
25% BM inﬁltration deﬁned as limited or focal BM involvement.32 When
bilateral BM specimens were available, determination of the extent of BM
involvement depended on analysis of the sample with the greater degree
of inﬁltration by lymphoma.
Statistical analyses
Clinicopathologic features were compared between the groups by using
the independent samples t test for continuous variables and the χ2 test for
categorical variables. Progression-free survival was calculated from the
date of initial diagnosis to the time of recurrence, disease progression or
death from any cause. Overall survival was measured from the date of
initial diagnosis until death, regardless of the cause. Patients still alive were
censored at the date of the last contact. Progression-free survival and OS
were estimated by the Kaplan–Meier method and the log-rank test was
used for comparison between groups. The Cox proportional hazard model
was used for multivariate analysis to assess the independent effects of
prognostic variables on survival. The data were analyzed by SPSS V.22.0 for
Windows (SPSS Inc., Chicago, IL, USA). A two-sided P-value of o0.05 was
considered statistically signiﬁcant and multiple comparisons were assessed
by Bonferroni correction.
RESULTS
Patient characteristics
A total of 712 patients with DLBCL were enrolled in this study.
A total of 263 patients with BM positive for lymphoma consisted of
173 (65.8%) cases with concordant BM and 90 (34.2%) with
discordant BM involvement. The remaining 449 patients had
negative BM including 212 (47.2%) patients with advanced DLBCL
(stage III–IV). Clinical and pathologic characteristics according to
type of BM involvement were compared and summarized in
Tables 1 and 2, respectively. Given that either concordant or
discordant BM disease belongs to a category of advanced DLBCL,
we considered advanced DLBCL but with negative BM as an
independent group to exclude the inﬂuence of stage and
highlight the role of BM involvement.
The median age and the proportion of elderly patients (460
years) were similar for those with negative BM, including patients
with advanced DLBCL, as well as for patients with concordant or
discordant BM involvement. The concordant BM group contained
more females than males, which was signiﬁcantly different from
the other three groups. The concordant BM group was more likely
to have aggressive clinical features such as elevated LDH, poor PS,
B symptoms and high IPI scores than the negative BM group, even
compared with advanced DLBCL patients with negative BM. In
contrast, patients with discordant BM were less likely to have an
elevated LDH or B symptoms. Compared with patients with
negative BM (including advanced DLBCL patients), the concordant
BM group was more likely to express CD5 and MYC, harbor MYC
rearrangement, co-express MYC and BCL2 (double positive
lymphoma; DPL), and to be MYC/BCL2 double-hit lymphoma.
BCL2 overexpression was signiﬁcantly more common in patients
with concordant or discordant BM disease than in patients with
negative BM. The proportion of GCB subtype was higher in the
discordant BM group than in the negative BM group, concordant
BM group or advanced DLBCL with negative BM (83.3% vs 53.4%,
51.6%, 46.3%, respectively; Po0.001).
Positive BM involvement characteristics
Concordant BM disease was more likely to be associated with
extensive BM involvement than discordant disease was (57.0 vs
11.1%, Po0.001; Figure 1a). In all, 199 of 263 (75.7%) patients with
BM positive for lymphoma underwent bilateral BM biopsies. In
these patients, 125 (62.8%) were bilaterally positive and 74 (37.2%)
were positive on a single side; patients with BM positive on a
single side more often had limited BM involvement (75.7 vs 53.6%
for bilateral involvement, P= 0.019; Figure 1a). In 90 patients with
discordant BM involvement, precise histopathologic subtypes of
BM samples of 78 patients were conﬁrmed: 54 (69.2%) of 78
patients had low-grade follicular lymphoma, 14 (17.9%) small
lymphocytic leukemia/chronic lymphocytic lymphoma and 10
(12.8%) marginal zone lymphoma. Representative images of BM
involvement are shown in Figure 1 (b1–b8).
In this study, most of the patients were treated with front-line
R-CHOP; 40 (23.1%) of 173 patients with concordant BM were
initially treated with intensive regimens (R-Hyper-CVAD/MA
(rituximab, hyper-fractionated cyclophosphamide, vincristine, dox-
orubicin and dexamethasone alternating with high-dose metho-
trexate and cytarabine) or R-DA-EPOCH (rituximab, dose-adjusted
etoposide, prednisone, vincristine, cyclophosphamide and doxor-
ubicin); 14 (15.6%) of 90 patients with discordant BM lymphoma
received rituximab maintenance for at least 1 year after R-CHOP
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therapy. CNS prophylaxis (that is, intrathecal methotrexate and/or
intravenous high-dose methotrexate with or without cytarabine)
was given to 107 (61.8%) of patients with concordant BM and 13
(14.4%) of patients with discordant BM. As shown in Figure 1c,
complete response was achieved in 75 patients (83.3%) with
discordant BM lymphoma, which was a higher rate than that
achieved in 116 patients (67%) with concordant BM (P= 0.005).
Nevertheless, there was no signiﬁcant difference in the probability
of disease relapse (P= 0.526) and CNS relapse (P= 0.340) between
patients with discordant vs concordant BM involvement. In
addition, compared to patients with negative BM, concordant
BM disease had a similar CNS relapse rate (2.4 vs 1.6%, P= 0.503);
no signiﬁcant difference of CNS relapse rate (4.5 vs 1.6%, P= 0.072)
was seen in patients with discordant BM involvement. 39 patients
with concordant BM and 29 patients with discordant BM
lymphoma underwent a second non-BM tissue biopsy when
disease relapsed; the biopsy specimen was more likely to show
low grade lymphoma in the discordant BM group than in the
concordant BM group (37.9 vs 5.1%, Po0.001).
Prognostic signiﬁcance of BM involvement
At the time of analysis, the median follow-up duration was
51.1 months (range: 0.23–186.7). The survival of patients with
concordant BM involvement were signiﬁcantly worse than not
only patients with negative BM (5-year OS: 42.3 vs 67.7%,
Po0.001; 5-year PFS: 37.2 vs 60.6%, Po0.001) but also advanced
DLBCL with negative BM (5-year OS: 42.3 vs 57.2%, P= 0.007; 5-
year PFS: 37.2 vs 51.5%, P= 0.002) (Figures 2a and b). As for
patients with discordant BM involvement, the 5-year OS (70.0 vs
77.6%, P= 0.510) was comparable to patients with limited DLBCL
(stage I–II), the 5-year PFS was similar to advanced DLBCL with
negative BM (49.7 vs 51.5%, P= 0.665) (Figure 2b).
Prognostic signiﬁcance of BM involvement incorporating IPI and
COO. Multivariate analysis incorporating the IPI and COO
subtypes was performed to illustrate the independent prognostic
signiﬁcance of different types of BM involvement (Supplementary
Table S1). Concordant BM lymphoma retained a negative
prognostic impact on OS and PFS, independent of the IPI and
COO subtypes (OS: RR = 1.396, P= 0.032; PFS: RR = 1.497, P= 0.006).
In contrast, discordant BM lymphoma had no prognostic effect on
OS and PFS in the multivariate analysis. When examining the
outcome of patients with high IPI scores or in non-GCB patients,
the prognostic value of concordant lymphoma in the BM was
evident (Supplementary Figure S1).
Development of BM-adjusted IPI. The univariate analysis of
baseline features in 263 patients with concordant or discordant
BM involvement revealed that age 460 years, PS 41, elevated
LDH, B symptoms, concordant BM involvement, high Ki-67 and
non-GCB subtype adversely affected OS, whereas extranodal sites
41 and bulky mass did not (Supplementary Figure S2). Following
multivariate analysis, age 460 years, PS 41 and concordant BM
involvement were independent predictors of OS (Table 3).
Thereby, a BM-adjusted IPI for patients with positive BM was
constructed by using three clinical parameters, each equal to one
point; four risk categories were generated: low (0 point), low-
intermediate (1 point), high-intermediate (2 points) and high
(3 points). Based on this risk-stratiﬁcation model, patients assigned
to the low-risk group had relatively good outcomes (5-year OS:
77.3%), and high-risk patients experienced extremely poor
outcomes (5-year OS: 16.5%; Figure 2c). The similar results were
observed when we randomly divided 263 patients with positive
BM into the training (n= 132) and validation (n= 131) sets
(Supplementary Figure S3).
Table 1. Clinical characteristics of patients grouped by type of BM involvement
Characteristics Negative BM
(n=449)
No. (%)
Concordant BM
(n= 173)
No. (%)
Discordant BM
(n= 90)
No. (%)
P-value Advanced DLBCL
and negative BM
(n= 212)
No. (%)
P-value
Neg vs Con Neg vs Dis Con vs Dis Adv-Neg
vs Con
Adv-Neg
vs Dis
Age (years)
Median 62.6 63.0 63.0 0.841 0.715 0.838 62.0 0.950 0.814
Range 16–89 25–91 31–89 17–89
Sex
Male 267 (59.5) 81 (46.8) 54 (60.0) 0.004 0.925 0.042 123 (58.0) 0.029 0.749
Female 182 (40.5) 92 (53.2) 37 (40.0) 89 (42.0)
IPI factors
Age 460 years 255 (56.8) 101 (58.4) 51 (56.7) 0.720 0.982 0.789 121 (57.1) 0.911 0.948
LDH elevated 240 (57.4) 138 (80.2) 34 (38.2) o0.001 0.001 o0.001 134 (66.0) 0.003 o0.001
Stages III–IV 212 (47.9) 173 (100.0) 90 (100.0) o0.001 o0.001 1.000 212 (100.0) 1.000 1.000
ECOG PS⩾ 2 53 (12.8) 63 (36.6) 10 (11.2) o0.001 0.691 o0.001 39 (19.7) o0.001 0.078
Extranodal sites41 63 (14.1) 115 (66.5) 55 (61.1) o0.001 o0.001 0.388 61 (28.9) o0.001 o0.001
IPI score
Low (0–1) 173 (39.9) 6 (3.5) 11 (12.4) o0.001 o0.001 o0.001 21 (10.2) o0.001 0.861
Intermediate (2–3) 214 (49.3) 85 (49.4) 58 (65.1) 138 (67.4)
High (4–5) 47 (10.8) 81 (47.1) 20 (22.5) 46 (22.4)
Bulky mass ⩾ 7 cm 108 (28.5) 50 (30.1) 28 (31.1) 0.700 0.623 0.869 60 (32.8) 0.586 0.781
B symptoms 141 (32.4) 100 (58.1) 18 (20.0) o0.001 0.02 o0.001 97 (46.6) 0.028 o0.001
Abbreviations: Adv-Neg, advanced DLBCL with negative BM involvement; BM, bone marrow; Con, concordant BM involvement; Dis, discordant BM
involvement; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate
dehydrogenase; Neg, negative BM involvement; PS, performance status.
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Prognostic signiﬁcance of the extent of BM involvement and
treatment in patients with concordant vs discordant BM disease
Extensive BM involvement compared with limited BM lymphoma
did not lead to worse OS (P= 0.969) or PFS (P= 0.960) in the
concordant BM subset (Figure 3a). However, in patients with
discordant BM disease, limited BM involvement seemingly
indicated a better OS (71.7 vs 50.0%, P= 0.051; Figure 3a).
For concordant BM group, patients treated with intensive
regimens had better 5-year OS (71.1 vs 34.5%, Po0.001) and
PFS (66.4 vs 28.0%, Po0.001) than patients accepting R-CHOP
(Figure 3b); after controlling two remaining BM-adjusted IPI factors
(age and PS), the survival beneﬁt from intensive chemotherapy
still existed (Supplementary Table S2). In patients with discordant
BM, rituximab maintenance brought a 5-year OS (92.3 vs 65.8%,
P= 0.007) and PFS (69.2 vs 46.1%, P= 0.038) beneﬁt in comparison
with observation after R-CHOP (Figure 3b).
Prognostic signiﬁcance of biomarkers in concordant vs negative
BM groups
We compared the prognostic signiﬁcance of these adverse
biomarkers independently and in combination summarized in
Table 2 in concordant vs negative BM groups and estimated the
prognostic power of concordant BM lymphoma relative to these
biomarkers. Non-GCB/ABC, high Ki-67, CD5, p53 expression and
MYC/BCL2 DPL predicted signiﬁcantly or borderline inferior
survival in both patients with concordant and negative BM,
whereas BCL2 or MYC expression, BCL2 or MYC rearrangement and
TP53 mutation lost their prognostic power in concordant BM
group. Concordant BM disease remained a signiﬁcant negative
predictor in each of above-mentioned biomarker-positive subsets
except in MYC/BCL2 double-hit lymphoma (DHL) subgroup
(Supplementary Figure S4).
Table 2. Pathologic characteristics of patients grouped by type of BM involvement
Characteristics Negative BM
(n= 449)
No. (%)
Concordant BM
(n=173)
No. (%)
Discordant BM
(n = 90)
No. (%)
P–value Advanced DLBCL
and negative BM
(n= 212) No. (%)
P-value
Neg vs Con Neg vs Dis Con vs Dis Adv-Neg
vs Con
Adv-Neg
vs Dis
COO
GCB 233 (53.4) 63 (51.6) 50 (83.3) 0.725 o0.001 o0.001 95 (46.3) 0.354 o0.001
Non-GCB 203 (46.6) 59 (48.4) 10 (16.7) 110 (53.7)
Ki-67 index
⩾ 70 283 (65.4) 91 (71.7) 30 (54.5) 0.185 0.115 0.025 143 (69.8) 0.713 0.034
o70 150 (34.6) 36 (28.3) 25 (45.5) 62 (30.2)
CD5 expression
Positive 17 (4.0) 25 (19.1) 6 (9.5) o0.001 0.052 0.089 8 (3.9) o0.001 0.081
Negative 411 (96.0) 106 (80.9) 57 (90.5) 196 (96.1)
BCL2 expression
positive 247 (57.4) 92 (75.4) 40 (87.0) o0.001 o0.001 0.104 127 (62.6) 0.017 0.001
negative 183 (42.6) 30 (24.6) 6 (13.0) 76 (37.4)
MYC expression
Positive 132 (31.3) 28 (58.3) NA 0.001 NA NA 70 (35.7) 0.004 NA
negative 290 (68.7) 20 (41.7) NA 126 (64.3)
BCL2/MYC DPL
positive 85 (19.9) 19 (31.1) 0 (0.0) 0.045 0.266 0.139 47 (23.7) 0.246 0.214
negative 342 (80.1) 42 (68.9) 5 (100.0) 157 (79.3)
BCL2 rearrangement
positive 65 (18.5) 20 (28.6) 6 (26.1) 0.056 0.370 0.818 38 (22.8) 0.342 0.722
negative 286 (81.5) 50 (71.4) 17 (73.9) 129 (77.2)
MYC rearrangement
positive 31 (11.0) 21 (34.4) 1 (16.7) o0.001 0.662 0.377 17 (12.1) o0.001 0.736
negative 251 (89.0) 40 (65.6) 5 (83.3) 124 (87.9)
BCL2/MYC DHL
Positive 9 (2.6) 9 (12.9) 0 (0.0) o0.001 0.443 0.077 4 (2.4) 0.001 0.460
negative 336 (97.4) 61 (87.1) 22 (100.0) 161 (97.6)
p53 expression
positive 129 (35.1) 19 (45.2) NA 0.193 NA NA 64 (37.4) 0.352 NA
negative 239 (64.9) 23 (54.8) NA 107 (62.6)
TP53 mutation
positive 79 (20.8) 10 (23.3) NA 0.707 NA NA 40 (22.9) 0.956 NA
negative 301 (79.2) 33 (76.7) NA 135 (77.1)
Abbreviations: Adv-Neg, advanced DLBCL with negative BM involvement; BM, bone marrow; Con, concordant BM involvement; COO, cell-of-origin; Dis,
discordant BM involvement; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell-like; Neg, negative BM involvement; NA, not available.
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Gene expression signature of concordant BM involvement
To unfold the potential molecular basis underlying the aggressive
clinical course of patients with concordant BM, we proﬁled and
compared the GEP results of DLBCL with concordant vs negative
BM involvement (Figure 4a). Thirty-four genes were differentially
expressed, including 32 genes upregulated and only 2 genes
downregulated in the concordant BM group (false discovery rate
= 0.1; Po0.001; Table 4a). Among the 32 upregulated genes, 10
genes were involved in cell metabolism; 6 participated in signaling
pathways and cell cycle regulation; RND2, GPR111, PPP1R9A and
PRG4 encoded various proteins playing a key role in cellular
adhesion or cytoskeletal reorganization; GATAD1, GTF3A, ZRSR2,
SRPX and MEOX2 were transcriptional regulators; and TIMD4,
CLEC4G and HP linked with immune response. We further
compared the GEP results between DLBCL in patients with
concordant BM involvement and patients with advanced DLBCL
without BM involvement (Figure 4b). Seventeen genes differen-
tially expressed were picked out (false discovery rate = 0.15;
Po0.001; Table 4b); 12 (70.6%) of which were also identiﬁed in
the former comparison.
We compared the GEP results between low (score: 1) and high
BM-adjusted IPI (score: 2 or 3) subgroups and between MYC+ and
MYC− subgroups with concordant BM involvement (Figure 4c).
A total of 56 genes were differentially expressed in the former
comparison and 26 differentially expressed genes were deter-
mined in the latter. Information about these genes is listed in
Supplementary Tables S3 and S4.
DISCUSSION
In the current clinical practice, positive BM involvement (whether
concordant or discordant) in DLBCL is generally recognized as
high-risk advanced disease and is treated with the same
immunochemotherapy regimen.33,34 This study, enrolling the
largest number of de novo DLBCL patients with positive BM
involvement to date, allowed valuable and effective analysis and
conﬁrmed that there is heterogeneity in the positive BM cohort.
It is well-known that patients with concordant BM involvement
have a poor prognosis; however, the impact of discordant BM on
the outcome of DLBCL patients remains controversial and even
contradictory.7,8,35 Our study showed distinct observations: the OS
Figure 1. Characteristics of patients with BM positive for lymphoma. (a) Percentage of limited vs extensive BM involvement in concordant
(Con) vs discordant (Dis) groups and double-positive BM involvement in bilateral BM biopsies (DP/BB) vs single-positive BM involvement in
bilateral BM biopsies (SP/BB) groups. (b) A representative illustration of morphologic and immunophenotypic proﬁling of BM specimens in
Con and Dis groups. Two DLBCL patients with 70% (b1) and 100% (b2) BM involvement; DLBCL cells are positive for CD20 (b3) with
proliferation index Ki-67 (b4) at 80%; one FL case with paratrabecular involvement (b5, b6). FL cells are positive for PAX-5 (b7) and BCL2 (b8).
Magniﬁcation × 20 and ×40. (c) Percentage of complete response, relapse and CNS relapse in Con vs Dis groups. Pie charts showing the
proportions of different pathologic subtypes of second biopsy when relapse occurs in Con vs Dis groups. FL, follicular lymphoma; Con,
concordant; Dis, disconcordant.
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of patients with discordant BM involvement unexpectedly was
comparable to that of patients with limited DLBCL; however, PFS
remained poor, similar to that of advanced DLBCL with negative
BM. Moreover, we found that concordant BM involvement
demonstrated even poorer OS and PFS than did advanced DLBCL
but with negative BM. These ﬁndings further emphasize the worse
outcome of DLBCL patients with concordant BM and the different
prognosis of patients with concordant vs discordant BM involve-
ment. In addition, we noted that the difference in PFS curves
between discordant and concordant BM groups seemingly
disappeared at 10 years later; based on the second biopsy
pathology, patients with discordant BM were more likely to have
indolent or low-grade lymphoma recurrence when BM was
involved. These information are useful to help clinicians to design
the BM status-based disease surveillance strategies.
Compared with the negative BM group, which has the largest
proportion of low IPI scores, concordant BM large B-cell
lymphoma is associated with a higher frequency of high IPI
scores; patients with discordant BM involvement more often
have intermediate IPI scores. This difference is attributed to
groups’ differing probabilities of having poor-risk clinical
features encompassed by the IPI. Along with the IPI, the COO
classiﬁcation is widely accepted as a biological predictor in
clinical practice. The results of our study showed that there is a
similar proportion of the non-GCB subtype between concordant
and negative BM groups and a signiﬁcantly greater proportion
of the GCB subtype in the discordant BM group; these ﬁndings
Figure 2. Survival curves for OS and PFS according to type of BM disease. (a) Comparisons of OS and PFS among negative, discordant and
concordant BM involvement groups. (b) Comparisons of OS and PFS among limited DLBCL with negative BM involvement (Lim-Neg),
advanced DLBCL with negative BM involvement (Adv-Neg), discordant BM and concordant BM groups. (c) The BM-adjusted IPI for risk
stratiﬁcation in patients with positive BM involvement. L, low risk; L-I, low-intermediate risk; H-I, high-intermediate risk; H, high risk.
Table 3. Prognostic factors of OS according to multivariate selection
in patients with positive BM involvement
Positive BM involvement (n=263) RR 95% CI P-value Score
Age 460 years 2.376 1.432–3.943 0.001 1
Elevated LDH 1.239 0.667–2.303 0.498
ECOG PS⩾ 2 1.757 1.027–3.005 0.040 1
B symptoms 1.549 0.914–2.626 0.104
Concordant BMI 1.997 1.079–3.696 0.028 1
Non-GCB 0.925 0.553–1.546 0.766
High Ki-67 1.469 0.810–2.665 0.206
Abbreviations: BM, bone marrow; BMI, body mass index; CI, conﬁdence
interval; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center
B-cell-like; LDH, lactate dehydrogenase; OS, overall survival; PS, perfor-
mance status; RR, relative risk.
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are not in agreement with those of Park et al.7 of Korea, who
observed a greater frequency of the non-GCB subtype in
patients with concordant BM involvement. The discrepant
results may be explained by the variation in ethnic groups and
the size of the two studies. Although different types of BM
involvement have a signiﬁcant correlation with different IPI
scores and COO subtypes, concordant BM involvement provides
additional prognostic information beyond that conferred by the
IPI and COO classiﬁcation.
Considering the independent prognostic signiﬁcance of con-
cordant BM involvement, current IPI systems, including the
standard IPI, the revised IPI and the NCCN-IPI, have an inevitable
defect, especially for DLBCL patients with a positive BM, for whom
they equalize concordant and discordant BM involvement.
Consequently, we used multivariate analysis in the context of
patients with positive BM lymphoma to develop a BM-adjusted IPI,
which includes three independent prognostic factors: concordant
BM involvement, age 460 years and PS 41; extranodal sites 41
Figure 3. Survival curves for OS and PFS according to the extent of BM involvement and treatment in concordant and discordant BM groups.
Limited BMI indicates limited BM involvement; Extensive BMI, extensive BM involvement; R maintenance, rituximab maintenance after
induction therapy; Observation, observation after induction therapy.
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and elevated LDH that are included in the current IPI systems are
excluded because they have no independent prognostic sig-
niﬁcance. The BM-adjusted IPI is easy to use, is reasonable for
DLBCL patients with positive BM involvement, and is potent in
distinguishing the four risk groups.
In this study, extensive BM involvement was more often seen
with concordant than with discordant BM disease and limited BM
involvement was more likely in patients with unilateral involve-
ment by lymphoma. Similar results were reported by Chuang
et al.4 in the pre-rituximab era, despite the different cut-off values
for distinguishing extensive from limited BM involvement.
Interestingly, when we explored the prognostic signiﬁcance of
the extent of BM involvement in the concordant BM group,
patients with limited BM involvement had the same poor survival
as did those with extensive BM disease; however, in the discordant
BM group, patients with limited BM involvement had a signiﬁcant
trend for longer survival than did those with extensive BM
involvement. These phenomena illustrate that (1) the extent of BM
involvement should be considered as one of the key points of
differential diagnosis between concordant and discordant BM
disease; (2) the importance of bilateral BM biopsies, as reported by
Juneja et al.,36 should be emphasized once again because
unilateral biopsies might ‘miss’ positive BM involvement in some
patients, in particular those with limited BM involvement; and (3)
the prognostic signiﬁcance of the extent of BM involvement in
different types of BM disease may be divergent.
Besides more often having poor-risk clinical features, the
concordant BM group has an increased probability for some
unfavorable molecular characteristics, which may contribute to
the dismal outcome of patients with concordant BM. Interestingly,
concordant BM disease remained an adverse predictor in almost
all of biomarker-positive subsets, whereas only part of frequently
used biomarkers retained their prognostic signiﬁcance for patients
with concordant BM, as did for patients with negative BM. These
ﬁndings suggest that concordant BM involvement may not be
entirely surrogate for these molecular features, and other possible
mechanisms to induce concordant BM involvement may under-
score the adverse biological events that should not be neglected.
Through the GEP analysis in this study, some differential
expression genes were revealed in the concordant BM group:
high expression level of metabolism-related genes and
transcription-activating genes may reﬂect a high proliferation
potency of lymphoma cells; although genes associated with
cellular adhesion or migration have not often been described in
lymphoma, such a signature in the metastases of solid tumors is
well-established;37 TIMD4 is a member of the T-cell immunoglo-
bulin and mucin domain gene family, which plays a critical role in
immunoregulation, and a high level of TIMD4 has been reported
as a negative regulator of antitumor immunity.38 Therefore, a
potential molecular basis underlying the development of con-
cordant BM disease may be related to tumor proliferation, cellular
adhesion or migration, and immune tolerance or escape.
Concordant BM group
MYC- MYC+
Con Neg Adv-Neg Con
Concordant BM group 
BMIPI-Low BMIPI-High
Figure 4. GEP heatmap in concordant BM involvement group. (a) GEP comparison between concordant and negative BM involvement groups.
(b) GEP comparison between concordant BM group and advanced DLBCL with negative BM involvement group. (c) GEP comparison between
high and low BM-adjusted IPI subsets in concordant BM group. GEP comparison between MYC+ and MYC− subsets in concordant BM group.
Con indicates concordant BM involvement; Neg, negative BM involvement; Adv-Neg, advanced DLBCL with negative BM involvement; BMIPI-
Low, low BM-adjusted IPI; BMIPI-High, high BM-adjusted IPI.
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Kremer et al.39 reported that a clonal relationship between the
low-grade inﬁltrates in the BM and DLBCL was conﬁrmed in the
two-thirds of patients with discordant BM disease, with the
remaining one-third exhibiting different clones as shown by
comparatively analyzing IGH and BCL2 rearrangements. In our
study, most patients with discordant BM disease had low-grade
follicular lymphoma in their BM samples, and displayed the
hallmark of DLBCL transformed from follicular lymphoma that the
proportions of GCB subtype and BCL2 overexpression are
signiﬁcantly higher than in pure de novo DLBCL.40 These data
further support the hypothesis that discordant BM disease is
considered as either an occult indolent B-cell lymphoma from
which DLBCL transformed or coincident indolent B-cell lymphoma
in DLBCL.
Some authors have recommended intensive immunochem-
otherapy as the initial therapy for high-risk DLBCL, and some
speciﬁc dose-intensive approaches such as R-Hyper-CVAD/MA or
R-DA-EPOCH could partly conquer the inferior prognosis caused
by MYC translocation, MYC/BCL2 co-expression and MYC/BCL2
double hit.41–44 We found that intensive regimens seemingly
resulted in longer survival than did R-CHOP for patients with
concordant BM. Also, likely due to the above hypothesis for
discordant BM involvement, the survival of this group appeared to
be prolonged by rituximab maintenance, just as this strategy
improved outcome in advanced indolent B-cell lymphoma.45,46 It
may be appropriate for patients with different types of BM disease
to accept precision treatment strategies, whereas this assumption
needs further study in future prospective clinical trials.
Although former studies have reported positive BM involve-
ment associated with an increased likelihood of CNS relapse in
DLBCL, universal application of CNS prophylaxis is not justiﬁed.47
Sehn et al.10 reported that without routine CNS prophylaxis,
concordant BM involvement was a signiﬁcant risk factor for CNS
relapse and there was a trend toward a slightly higher rate of CNS
relapse in patients with discordant BM. However, our study
showed different observation in which the frequency of CNS
relapse was not escalated in patients with concordant BM disease,
most of whom had received CNS prophylaxis. Therefore, the
difference in the two studies suggests CNS prophylaxis may
reduce the likelihood of CNS relapse.
In conclusion, this retrospective study provides a comprehen-
sive summary of clinical and biological features in DLBCL with BM
involvement in the rituximab era. Positive BM inﬁltration in DLBCL
represents a heterogeneous group of disorders. The BM-adjusted
IPI for patients with positive BM is an effective, valuable and
potent prognostic model for risk stratiﬁcation. Our ﬁndings
suggest that DLBCL with concordant BM involvement constitutes
a distinct subset with unfavorable gene expression signatures,
high-risk clinicopathologic features and poor prognosis.
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